Diagnostic screening programs help catch cancer, abnormalities or other diseases before they reach an advanced stage, saving lives and healthcare costs. Screening programs include, lung, breast, prostate, and cervical cancer, among many others.
In conjunction with prevention efforts, the introduction of screening examinations has resulted in a reduction of nearly 6 million cancer-related deaths since 1975.
Breast density is most often discussed within the context of cancer risk, but new research suggests that it also could be used as a marker of cardiometabolic health.
The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer.
Radiologists interpreting screening mammograms may be especially susceptible to falling victim to automation bias, as these exams are repetitive in nature.
Breast density is known to drop over time, but the rate at which density decreases merits special attention, as it could be associated with a woman’s chance of developing cancer.
That’s according to an award-winning scientific online poster presented this week during the American Roentgen Ray Society’s annual meeting being held in Honolulu, Hawaii.
Features pertaining to location, density and superimposed structures were recently found to be associated with poorer outcomes for patients who initially had their lung cancer overlooked on radiographs.
Since being approved by the U.S. Food and Drug Administration in 2011, DBT has become the most common method for breast cancer screening, and as of September 2022, 84% of all U.S. mammography screening facilities housed DBT units.
A team of experts with the University of Maryland School of Medicine recently presented ChatGPT with a set of questions relative to breast cancer screening recommendations to determine whether the program could reliably offer appropriate guidance.